Latest news
Debiopharm and Ascepion Pharmaceuticals, Inc. announce an exclusive license agreement for the development and commercialisation of the dual-targeting kinase Inhibitor,…
Debiopharm Presented Results at the ASCO 2012 Annual meeting – Results of Phase I study with Debio 0932, an oral…
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease
The Japanese Cancer Association and Debiopharm Group™ present Doctors Arakawa and Kurokawa with the 2011 ‘JCA-Mauvernay Award’for their innovative and…
Debiopharm Group™ presents the ‘Debiopharm Group™ Life Sciences Award 2011’ and two ‘Junior Debiopharm Group™ Awards 2011’ at the ISREC…
Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of…